Skip to main content

Peer Review reports

From: Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients

Original Submission
8 Feb 2021 Submitted Original manuscript
18 Feb 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 2
18 Feb 2021 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
7 Mar 2021 Reviewed Reviewer Report - Carlos Gustavo Wambier
17 Mar 2021 Reviewed Reviewer Report
29 Mar 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 4
29 Mar 2021 Submitted Manuscript version 4
5 Apr 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 5
5 Apr 2021 Submitted Manuscript version 5
6 Apr 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 6
6 Apr 2021 Submitted Manuscript version 6
7 Apr 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 7
7 Apr 2021 Submitted Manuscript version 7
7 Apr 2021 Author responded Author comments - Nurullah Okumuş
Resubmission - Version 8
7 Apr 2021 Submitted Manuscript version 8
Publishing
15 Apr 2021 Editorially accepted
4 May 2021 Article published 10.1186/s12879-021-06104-9

You can find further information about peer review here.

Back to article page